KURA ONCOLOGY, INC.: 10-K filed 2014-03-31

Name: KURA ONCOLOGY, INC.: 10-K filed 2014-03-31
Creator: KURA ONCOLOGY, INC.

What KURA ONCOLOGY, INC. reported in its annual report filed 2014-03-31 (fiscal FY 2013): 16 published measures, 51 facts as tagged in accession 0001213900-14-001896.

This filing

Form: 10-K (annual report)
Filed: 2014-03-31
Fiscal period: fiscal FY 2013
Accession: 0001213900-14-001896 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All KURA ONCOLOGY, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2013-12-31	9,068	USD
At 2012-12-31	8,302	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2013-12-31	133,025	USD
At 2012-12-31	103,648	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2013-12-31	-123,957	USD
At 2012-12-31	-95,346	USD
At 2011-12-31	-68,031	USD
At 2010-12-31	-40,991	USD
At 2009-12-31	-18,596	USD
At 2008-12-31	1,400	USD
At 2007-12-31	35,023	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2013-12-31	6,568	USD
At 2012-12-31	4,802	USD
At 2012-09-30	5,586	USD
At 2011-12-31	4,220	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	-28,611	USD	365
2007-11-17 to 2013-12-31	-173,957	USD	2237
2012-01-01 to 2012-12-31	-27,315	USD	366
2011-01-01 to 2011-12-31	-27,040	USD	365
2010-01-01 to 2010-12-31	-22,395	USD	365
2009-01-01 to 2009-12-31	-19,996	USD	365
2008-01-01 to 2008-12-31	-33,623	USD	366
2007-11-17 to 2007-12-31	-14,977	USD	45

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	-23,234	USD	365
2007-11-17 to 2013-12-31	-153,432	USD	2237
2012-01-01 to 2012-12-31	-24,418	USD	366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	25,000	USD	365
2007-11-17 to 2013-12-31	160,000	USD	2237
2012-01-01 to 2012-12-31	25,000	USD	366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	-22,734	USD	365
2007-11-17 to 2013-12-31	-156,782	USD	2237
2012-01-01 to 2012-12-31	-22,341	USD	366

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	5,877	USD	365
2007-11-17 to 2013-12-31	17,175	USD	2237
2012-01-01 to 2012-12-31	4,974	USD	366

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2013-12-31	350	USD
At 2012-12-31	1,850	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2013-12-31	5,000,000	shares
At 2012-12-31	5,000,000	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2013-12-31	49,500	USD
At 2012-12-31	49,500	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2013-12-31	5,500	USD
At 2012-12-31	5,500	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	22,734	USD	365
2007-11-17 to 2013-12-31	141,139	USD	2237
2012-01-01 to 2012-12-31	22,341	USD	366

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2007-11-17 to 2013-12-31	50,000	USD	2237
2007-11-17 to 2007-12-31	50,000	USD	45

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	-1,500	USD	365
2007-11-17 to 2013-12-31	350	USD	2237
2012-01-01 to 2012-12-31	-1,077	USD	366

Inspect the source

Entity: KURA ONCOLOGY, INC. / CIK 0001422143
Captured: 2026-09-20T08:03:22.155Z
SEC response SHA-256: 99c25996d2b94a162f8d422ab44911c7e1eca886397d9f5849b0bd5c004a4e4f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001422143.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))